Review
Oncology
Claudia Trojaniello, Jason J. Luke, Paolo A. Ascierto
Summary: Melanoma, the most fatal skin cancer, has seen a significant revolution in treatment since 2011 with targeted therapy and immunotherapy. Current research focuses on preventing resistance, increasing drug effectiveness, and exploring new treatment combinations and targets to benefit more patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Jing Zhan, Manli Zhang, Lili Zhou, Chuan He
Summary: The present study developed a synergistic strategy by combining in situ tumor vaccines, gene-mediated downregulation of tumor angiogenesis, and anti-PD-L1 therapy to address several key problems in tumor immunotherapy. This strategy can enhance the activation of effector T cells, improve tumor invasion and immune killing ability, and increase treatment response rate.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Article
Immunology
Qi-jie Zhang, Jiao-chen Luan, Le-bin Song, Rong Cong, Cheng-jian Ji, Xiang Zhou, Jia-dong Xia, Ning-hong Song
Summary: The study found no difference in efficacy between elderly and young patients in most cancer types, except for melanoma patients receiving anti-PD-1 therapy. Elderly patients showed higher treatment response rate and more favorable prognosis in certain cancer types, potentially attributed to their high mutational properties. This suggests that modulating immune function could be beneficial to immunotherapy in elderly patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Chemistry, Multidisciplinary
Jaehyun Kim, Juhyeong Hong, Jieun Lee, Shayan Fakhraei Lahiji, Yong-Hee Kim
Summary: Cancer immunotherapy has greatly improved the standard of care for solid tumors, with immune checkpoint blockade targeting immunosuppressive mechanisms. However, the overall response rate to immune checkpoint blockades is low, with some patients experiencing severe immune-related adverse events. The failure of immune checkpoint blockades is primarily attributed to the tumor microenvironment, leading to current research focusing on targeting and suppressing the immunosuppressive characteristics within the tumor microenvironment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Oncology
Sydney Ch'ng, Semra Uyulmaz, Matteo S. Carlino, Thomas E. Pennington, Kerwin F. Shannon, Michael Rtshiladze, Jonathan R. Stretch, Omgo E. Nieweg, Alexander H. R. Varey, Edward Hsiao, Rony Kapoor, Ines Pires da Silva, Serigne N. Lo, Andrew J. Spillane, Richard A. Scolyer, Georgina Long, Angela M. Hong, Robyn P. M. Saw, John F. Thompson, Alexander M. Menzies
Summary: Surgery has been traditionally important in treating oligometastatic stage IV melanoma patients, but with the development of effective systemic therapies, especially immunotherapy, the role of surgery has evolved. The decision between upfront surgery and immunotherapy needs to be made in a specialist melanoma multidisciplinary setting tailored to individual patient and tumor factors. High-level clinical trial evidence is necessary to address uncertainties in managing these patients, though the complexity of disease presentations may pose challenges in trial design.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Immunology
Emily J. Lelliott, Grant A. McArthur, Jane Oliaro, Karen E. Sheppard
Summary: The recent development of targeted and immune-based therapies has revolutionized melanoma treatment, with ongoing exploration of combination therapies. The combination of BRAF, MEK, and CDK4/6 inhibitors holds promise for new treatment approaches, while immunotherapy is increasingly being utilized in melanoma patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Armita Mahdavi Gorabi, Mehrnaz Sadat Ravari, Mohammad-Javad Sanaei, Soodabeh Davaran, Prashant Kesharwani, Amirhossein Sahebkar
Summary: Surgical resection is a promising treatment for early-stage melanoma, while targeted therapy with immune checkpoint blockades (ICBs) has shown significant outcomes in advanced cases. However, the non-specific targeting and immune-related adverse events of ICBs have led to the emergence of a new platform using nanoparticles (NPs) for localized drug delivery.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Engineering, Environmental
Yongbo Zhang, Xu He, Yongteng Zhang, Yanping Zhao, Siyu Lu, Yongjun Peng, Ligong Lu, Xianglong Hu, Meixiao Zhan
Summary: This study introduces a novel immunomodulator nanoparticle that targets tumor cell mitochondria, combined with photothermal therapy and immune checkpoint blockade to enhance antitumor immune response, effectively suppressing tumor recurrence and metastasis.
CHEMICAL ENGINEERING JOURNAL
(2021)
Review
Immunology
Lothar C. C. Dieterich
Summary: This review discusses the mechanistic insights into the role of melanoma-derived extracellular vesicles (EVs) in tumor immune evasion and immune regulation, and highlights the current challenges in the field.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Elizabeth I. Buchbinder, Jason L. Weirather, Michael Manos, Brian J. Quattrochi, Lynette M. Sholl, Ryan C. Brennick, Peter Bowling, Nancy Bailey, Lisa Magarace, Patrick A. Ott, Rizwan Haq, Benjamin Izar, Anita Giobbie-Hurder, F. Stephen Hodi
Summary: Mucosal melanoma, a rare form of melanoma, can be effectively treated with immune checkpoint blockade (ICB) despite lower response rates compared to cutaneous melanomas. A study found no significant correlation between mutational burden and response to ICB in mucosal melanoma patients, indicating the need for further exploration in this patient population. Genetic differences were observed in mucosal melanoma compared to cutaneous melanoma, highlighting the importance of additional research in this area.
Article
Materials Science, Multidisciplinary
Xingyu Zhao, Yu Han, Yang Sun, Wei Feng, Jianguo Liu, Dongsong Li, Tiejun Wang
Summary: This study developed a multi-approach treatment strategy for osteosarcoma by combining photothermal ablation-based in situ tumor vaccine with PD-1/PD-L1 blockade immunotherapy. The strategy enhances the specific killing effect of T cells on tumor cells by generating in situ tumor vaccine and activating DCs.
MATERIALS & DESIGN
(2021)
Article
Engineering, Biomedical
Maoyuan Sun, Yan Li, Wenli Zhang, Xiang Gu, Rong Wen, Ke Zhang, Jinning Mao, Chengyao Huang, Xiong Zhang, Mao Nie, Zhiwen Zhang, Chao Qi, Kaiyong Cai, Guodong Liu
Summary: In this study, a biomimetic nanoplatform AMNP@CLP@CCM was developed for the targeted photothermal therapy and immune checkpoint blockade (ICB) treatment of glioblastoma (GBM). The nanoplatform successfully crossed the blood-brain barrier and delivered the immune checkpoint inhibitor CLP002 to GBM tissues. The photothermal therapy not only enhanced blood-brain barrier penetration but also stimulated immunogenic cell death and T lymphocyte infiltration, resulting in significant growth inhibition of orthotopic GBM.
ACTA BIOMATERIALIA
(2023)
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Review
Chemistry, Multidisciplinary
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Davood Bashash
Summary: This review provides an overview of the current research status of immune checkpoint blockades in breast cancer and discusses the efficacy and limitations of ICB therapy in breast cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Oncology
Nayan Lamba, Andrew Groves, Matthew Torre, Kee Kiat Yeo, J. Bryan Iorgulescu
Summary: This study evaluates the epidemiology of primary and metastatic pediatric brain tumors in the United States based on the WHO CNS 4th and 5th editions classifications. The results show the prevalence and characteristics of different types of tumors in pediatric patients, highlighting the differences in age distribution and racial/ethnic predisposition. The study provides important insights into the understanding of pediatric brain tumors.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Mary Jane Lim-Fat, Gilbert C. Youssef, Mehdi Touat, J. Bryan Iorgulescu, Sydney Whorral, Marie Allen, Rifaquat Rahman, Ugonma Chukwueke, J. Ricardo McFaline-Figueroa, Lakshmi Nayak, Eudocia Q. Lee, Tracy T. Batchelor, Omar Arnaout, Pier Paolo Peruzzi, E. Antonio Chiocca, David A. Reardon, David Meredith, Sandro Santagata, Rameen Beroukhim, Wenya Linda Bi, Keith L. Ligon, Patrick Y. Wen
Summary: Targeted gene panel utilization remains low for therapy selection in GBM-IDHwt. Improvement in targeted therapy and clinical trial design is needed to fully leverage the potential of NGS in clinical care.
Article
Endocrinology & Metabolism
Luz E. Castellanos, Catherine Gutierrez, Timothy Smith, Edward R. Laws, J. Bryan Iorgulescu
Summary: This study examined the epidemiology of adult pituitary tumors, focusing on both common and uncommon types using the 2017 WHO classification. The majority of pituitary tumors were pituitary adenomas, with microadenomas more common in females and macroadenomas/giant adenomas more common in males. The study also found variations in tumor types based on race/ethnicity, tumor size, and overall survival rates.
Article
Surgery
Cheryl K. Zogg, Zara Cooper, Peter Peduzzi, Jason R. Falvey, Mary E. Tinetti, Judith H. Lichtman
Summary: The objective of this study is to identify and quantify three new postdischarge quality-metrics for older trauma patients, including mortality, readmission, and patients' average number of healthy days at home. These metrics provide a more comprehensive assessment of older adult trauma care and recovery.
Article
Oncology
Quinn T. Ostrom, Madison L. Shoaf, Gino Cioffi, Kristin Waite, Carol Kruchko, Patrick Y. Wen, Daniel J. Brat, Jill S. Barnholtz-Sloan, J. Bryan Iorgulescu
Summary: This study utilized data from the U.S. National Cancer Database to estimate the national-level overall survival patterns of molecularly-defined diffuse gliomas. The findings demonstrate differences in survival rates among different glioma types, and the impact of WHO grade and MGMT promoter methylation on survival.
Article
Clinical Neurology
Matthew Torre, Patrick Y. Wen, J. Bryan Iorgulescu
Summary: Partial methylation of the MGMT promoter is predictive of improved overall survival in patients with IDH-wildtype glioblastoma treated with first-line single-agent chemotherapy, supporting the use of temozolomide therapy in these patients.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Oncology
Joseph Toker, J. Bryan Iorgulescu, Alexander L. Ling, Genaro R. Villa, Josephina A. M. A. Gadet, Laxmi Parida, Gad Getz, Catherine J. Wu, David A. Reardon, E. Antonio Chiocca, Marco Mineo
CLINICAL CANCER RESEARCH
(2023)
Letter
Oncology
J. Bryan Iorgulescu
Article
Cardiac & Cardiovascular Systems
Cheryl K. Zogg, Sameer A. Hirji, Edward D. Percy, Paige C. Newell, Pinak B. Shah, Tsuyoshi Kaneko
Summary: Limited data are available on the comparison of postdischarge perioperative outcomes between isolated valve-in-valve transcatheter mitral valve replacement (VIV-TMVR) and surgical reoperative mitral valve replacement (re-SMVR) on a nationwide scale. This study aimed to assess the contemporary postdischarge outcomes of VIV-TMVR and re-SMVR using a large national multicenter longitudinal database. The results showed that VIV-TMVR was associated with lower major morbidity, shorter hospital stays, and increased likelihood of discharge home compared to re-SMVR.
AMERICAN JOURNAL OF CARDIOLOGY
(2023)
Article
Clinical Neurology
Mackenzie Price, Katherine Ryan, Madison L. Shoaf, Corey Neff, J. Bryan Iorgulescu, Daniel B. Landi, Gino Cioffi, Kristin A. Waite, Carol Kruchko, Jill S. Barnholtz-Sloan, Quinn T. Ostrom
Summary: This report summarizes the latest population-based incidence, mortality, and survival data for primary brain and other CNS tumors in the US, aiming to serve as a concise resource for neuro-oncology providers.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Oncology
J. Bryan Iorgulescu, Leah K. Shaw, Asif Rashid, Priya Rao, Sreedhar Mandayam, Keyur P. Patel, Kathleen M. Schmeler, Richard K. Yang, Pavlos Msaouel
Summary: This case report highlights the importance of molecular testing in determining the origin of tumors in solid organ transplant patients. It describes a rare case of metastatic Mullerian type clear cell carcinoma originating from ectopic Mullerian tissue in a transplanted kidney. The tumor showed resistance to chemotherapy and immunotherapy, suggesting the need for further investigation in similar transplant recipients.
Article
Oncology
Alexander G. Yearley, Julian Bryan Iorgulescu, Ennio Antonio Chiocca, Pier Paolo Peruzzi, Timothy R. Smith, David A. Reardon, Michael A. Mooney
Summary: This review provides a curated overview of current databases and registries related to glioma research, with a total of 20 databases identified and reviewed. These databases cover data collection from 1975 to 2022, including over 100 clinical variables and 12 molecular data types. While many databases offer large sample sizes and a wide variety of variables, some have limitations such as complex data access requirements and a lack of glioma-specific variables.
NEURO-ONCOLOGY ADVANCES
(2022)
Article
Medicine, Research & Experimental
Patrick C. Lee, Susan Klaeger, Phuong M. Le, Keegan Korthauer, Jingwei Cheng, Varsha Ananthapadmanabhan, Thomas C. Frost, Jonathan D. Stevens, Alan Y. L. Wong, J. Bryan Iorgulescu, Anna Y. Tarren, Vipheaviny A. Chea, Isabel P. Carulli, Camilla K. Lemvigh, Christina B. Pedersen, Ashley K. Gartin, Siranush Sarkizova, Kyle T. Wright, Letitia W. Li, Jason Nomburg, Shuqiang Li, Teddy Huang, Xiaoxi Liu, Lucas Pomerance, Laura M. Doherty, Annie M. Apffel, Luke J. Wallace, Suzanna Rachimi, Kristen D. Felt, Jacquelyn O. Wolff, Elizabeth Witten, Wandi Zhang, Donna Neuberg, William J. Lane, Guanglan Zhang, Lars R. Olsen, Manisha Thakuria, Scott J. Rodig, Karl R. Clauser, Gabriel J. Starrett, John G. Doench, Sara J. Buhrlage, Steven A. Carr, James A. DeCaprio, Catherine J. Wu, Derin B. Keskin
Summary: This study reveals transcriptional suppression of HLA-I antigen presentation in Merkel cell carcinoma and identifies MYCL, PRC1.1, and USP7 as regulators in this process.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Cardiac & Cardiovascular Systems
Cheryl K. Zogg, Arman Avesta, Pramod N. Bonde, Arya Mani
Summary: Echocardiography has limitations in the diagnosis of infective endocarditis (IE), while other imaging techniques such as FDG-PET can provide more accurate diagnostic information.
EUROPEAN HEART JOURNAL-CASE REPORTS
(2022)